Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 400

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 400
---
 deferred checks through financial institutions, primarily from related parties for the sale of Heritas Diagnostics services. Net cash generated from / (used in) investing activities Net cash used in investing activities changed by $529,988, from a net cash outflow of $529,825 for the year ended June 30, 2023, to a net cash inflow of $163 for the year ended June 30, 2024. This change was primarily attributable to the absence of capitalized expenditures on intangible assets, in comparison to the prior year, which included capital investments related to the development of new diagnostic tests for the Heritas Diagnostics segment and the Rewell platform. It is important to note that, while the Company continued its research and development efforts related to the Rewell platform and the advancement of clinical genetic products during the year ended June 30, 2024, these expenditures were not capitalized. As outlined in the research and development expenses section, the increase in R&D costs was driven by outsourced third -partyservices for platform enhancements, and functional upgrades, as well as increased personnel expenses. However, these activities did not meet the capitalization criteria under IFRS and, in accordance with applicable accounting standards, were recorded as expenses, resulting in no capitalized intangible asset additions during the period. Net cash generated from financing activities Net cash generated from financing activities increased by $67,698, or 3.6%, from $1,867,214 for the year ended June 30, 2023, to $1,934,912 for the year ended June 30, 2024, primarily due to financing inflows from loans provided by shareholders and related parties in the year ended June 30, 2024, resulting from increased contributions by the Parent. Trend Information Please refer to “ — Key Factors Affecting Operating Results.” Off-Balance Sheet Arrangements The Company does not have any off -balancesheet arrangements. Quantitative and Qualitative Disclosures About Market Risk We are exposed to a variety of risks in the ordinary course of our business. These risks primarily include credit risk, liquidity risk and foreign currency risk. For more information about financial risks to which the Company is exposed, see note 3 to the Company’s audited combined financial statements included elsewhere in this proxy statement/prospectus. Credit Risk Credit risk refers to the risk that a counterparty will default on its contractual obligations, resulting in us incurring a financial loss. We are exposed to credit risk from its operating and financing activities